Intravesical Ty21a Treatment of Non–muscle-invasive Bladder Cancer Shows a Good Safety Profile

Standard-of-care immunotherapy for non–muscle-invasive bladder cancer (NMIBC) with intravesical Bacillus Calmettte-Guérin (BCG) is associated with adverse events (AEs), disease recurrence/progression, and supply shortages. Preclinical data have shown that intravesical instillation of Ty21a/Vivotif,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucca, Ilaria, Derré, Laurent, Cesson, Valérie, Bohner, Perrine, Crettenand, François, Rodrigues-Dias, Sonia, Dartiguenave, Florence, Masnada, Audrey, Texeira-Pereira, Carla, Benmerzoug, Sulayman, Chevalier, Mathieu, Domingos-Pereira, Sonia, Nguyen, Sylvain, Polak, Lenka, Schneider, Anna, Roth, Beat, Jichlinski, Patrice, Nardelli-Haefliger, Denise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Brief Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539774/
https://www.ncbi.nlm.nih.gov/pubmed/36212980
http://dx.doi.org/10.1016/j.euros.2022.09.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539774/
https://www.ncbi.nlm.nih.gov/pubmed/36212980
http://dx.doi.org/10.1016/j.euros.2022.09.004

Ejemplares similares